BRAF and non-small cell lung carcinoma: It has been well established that BRAF p.V600E mutation drives the activation of the MAPK signaling pathway and that BRAF is frequently mutated in different cancer types, including leukemia, melanoma, thyroid carcinoma, colorectal adenocarcinoma, glioblastoma, and non-small-cell lung cancer [23,24].